The global short-acting insulin market size is estimated to be valued at USD 10.00 Billion in 2025. It can reach a valuation of USD 14.35 Billion by 2032, by exhibiting a CAGR of 5.3% throughout the forecast period (2025-2032).
Short-acting insulin, also known as regular or bolus insulin, is taken before mealtimes to prevent blood glucose levels from spiking. The market growth is primarily driven by the global rise of Type I and Type II diabetes. Innovations in drugs for glucose management and the establishment of retail pharmacy chains for insulin vial refills can bode well for the market.
However, the high costs of insulin products can negatively impact the market growth.
Key Market Insights
The short-acting insulin market is likely to be shaped by the use of regular insulin in combination therapies and digital therapeutics for the management of diabetes.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/short-acting-insulin-market
Short-Acting Insulin Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 10.00 Billion |
|
Estimated Value by 2032 |
USD 14.35 Billion |
|
Growth Rate |
5.3% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The slashed prices of insulin pens and other delivery devices by major manufacturers such as Novo Nordisk, Eli Lilly, and Sanofi from January 2024 can boost the revenues of the short-acting insulin market. The capping of out-of-pocket patient prices and insurance policies covering insulin therapy costs can significantly boost the market growth. This can be driven by the expenses borne by patients amid the rise of insulin prices.
The development of insulin pumps and pens that deliver accurate dosages can drive sales among diabetics. The advantages of portability, ease of use, and large dosage markings can facilitate this trend.
The integration of digital therapeutics and continuous glucose monitoring devices can aid in the management of insulin levels for regular users. The inflated healthcare budgets of nations and the increased access to products for diabetics can spur innovation in delivery methods and drug formulations.
Market Opportunity: Development of Biosimilars
The development of biosimilar short-acting insulins can present a significant opportunity in the event of drug shortages or supply chain disruptions. Support from regulatory agencies like the U.S. Food & Drug Administration (FDA) and the development of cost-effective alternatives can bolster market revenues. Healthcare initiatives aimed at lowering drug prices can also drive the development of biosimilars in the short-acting insulin market.
Market Challenge: Discontinuation of Insulin Products
The discontinuation of insulin products such as Humulin and Humalog, coupled with the short supply of insulin pens like the Fiasp Flex shortage, can negatively impact the market growth. The phase-out of products and the lack of coverage of modern insulin products by insurance providers can spell bad news for diabetics.
Analyst’s View
Recent Developments
Novo Nordisk received approval for the launch of its drug, Awiqli, in South Korea on December 23, 2024. Although it is a long-acting insulin analog, it can be used as a bolus insulin for type 2 diabetics.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :